NR 546 Antipsychotics Table Week 3 Assignments.

NR 546 Antipsychotics Table Week 3 Assignments. Drug name Indication Target symptoms: state if positive or negative effect Potency (if noted. receptor occupancy if noted) Neurotransmitter(s) affected Half-life (T1/2), metabolism (CYP 450 enzyme) Notable side effects (associate to pathway or NT) Typical antipsychotics (conventional) Haloperidol Target symptoms: Manifestations of psychotic disorders Tics and vocal utterances in Tourette’s Syndrome Second-line treatment of severe behavior problems in children of combative, explosive, hyperexcitability Second-line short-term treatment of hyperactive children Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Bipolar Disorder Behavioral disturbances in dementias Delirium (with lorazepam) Positive symptoms of psychosis, violent or aggressive behavior Potency: High potency first-generation Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis and combative, explosive, and hyperactive behaviors Blocks dopamine 2 receptors in the nigrostriatal pathway, improving tics and other symptoms in Tourette’s syndrome Half-Life: Haldol decanoate: approximately 3 weeks Oral: 12-38 hours Metabolism: CYP1A2, CYP2D6, CYP3A4  Neuroleptic-induced deficit syndrome  Akathisia  Drug-induced parkinsonism  Tardive dyskinesia, dystonia  Irreversible involuntary dyskinetic movements  Galactorrhea, amenorrhea  Dizziness, sedation  Dry mouth  Constipation  Urinary retention  Blurred vision  Decreased sweating  Hypotension  Tachycardia  Hypertension  Weight gain Thioridazine Target symptoms: Used for Schizophrenia in patients who fail to respond to treatment with other antipsychotic drugs Positive symptoms of psychosis Half-Life: 21-24 hours Metabolism:  Neuroleptic-induced deficit syndrome  Akathisia  Priapism  Drug-induced parkinsonism Darah Cummins NR 546 Motor and autonomic hyperactivity Violent or aggressive behavior Potency: Low-potency first-generation Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis CYP450 2D6  Tardive dyskinesia  Irreversible involuntary dyskinetic movements  Galactorrhea, amenorrhea  Pigmentary retinopathy  Dizziness, sedation  Dry mouth  Constipation  Blurred vision  Decreased sweating  Sexual dysfunction  Hypotension  Weight gain Thiothixene Target symptoms: Schizophrenia, other psychotic disorders, bipolar disorder Reduces positive symptoms in schizophrenia Reduces symptoms of acute psychotic mania Reduces negative symptoms of psychosis Potency: High potency conventional antipsychotic Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis Half-Life: 34-35 hours Metabolism: CYP1A2  Neuroleptic-induced deficit syndrome  Akathisia  Drug-induced parkinsonism  Tardive dyskinesia  Irreversible involuntary dyskinetic movements  Galactorrhea, amenorrhea  Sedation  Dry Mouth  Constipation  Vision disturbance  Urinary retention  Hypotension  Tachycardia  Rare fine lenticular pigmentation Fluphenazine Target symptoms: Psychotic disorders, bipolar disorder Positive symptoms of psychosis Motor and autonomic hyperactivity Violent or aggressive behavior Potency: High potency conventional antipsychotic Half-Life: 14-16 hours Metabolism: CYP2D6  Neuroleptic-induced deficit syndrome  Akathisia  Drug-induced parkinsonism  Tardive dyskinesia  Irreversible involuntary dyskinetic movements Darah Cummins NR 546 Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis  Galactorrhea, amenorrhea  Dizziness, sedation  Dry mouth  Constipation  Urinary retention  Blurred vision  Decreased sweating  Depression  Sexual dysfunction  Hypotension  Tachycardia  Syncope  Weight gain.